1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

Orange County Entrepreneur Banks On Data-Based Approach To Detect, Treat Diseases

 
• By Marion Webb

IV BioHoldings CEO Marty Keiser connects data, technology, capital and people to create start-ups focusing on liquid biopsy programs.

Launch

IV BioHoldings launched three liquid biopsy start-ups aimed at early detection and treatment of cancer and one focusing on metabolic disease: LiquidLung, HepGene and Mammogen.

Incorporated in December 2018 and funded in March 2019 with a $1m seed round, LiquidLung focuses on the early detection of lung cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.